Effects of telmisartan on the expression of matrix metalloproteinase-13 and its tissue inhibitor-1 and insulin resistance in nonalcoholic steatohepatitis rat model
{"title":"Effects of telmisartan on the expression of matrix metalloproteinase-13 and its tissue inhibitor-1 and insulin resistance in nonalcoholic steatohepatitis rat model","authors":"Liu Jiangkui, Shen Yi-hui","doi":"10.3724/sp.j.1264.2011.00018","DOIUrl":null,"url":null,"abstract":"Objective To study the effects of telmisartan on matrix metalloproteinase-13(MMP-13) and tissue inhibitor of metallo- proteinase-1(TIMP-1) expressions and insulin resistance in rat model of nonalcoholic steatohepatitis(NASH).Methods Thirty male SD rats were randomized into normal control group,NASH model group and telmisartan intervention group.The rats were given standard food in normal control group,while high fat diet for 16 weeks in the other two groups to induce NASH.In telmisartan intervention group, telmisartan[5 mg/(kg·d)]was adminstrated intragastrically for 4 weeks since the 12th week.All animals were sacrificed at 16 weeks. Serum levels of alanine aminotransferase(ALT),aspartate transaminase(AST),fasting blood glucose(FBG) and fasting insulin(FINS) were detected.Insulin sensitivity was evaluated by homeostasis model assessment of insulin resistance(HOMA-IR).Western blot and RT-PCR were used to measure TIMP-1 and MMP-13 expressions in hepatic tissue.Histological observation and immunohistochemical staining ofα-smooth muscle actin(α-SMA) were also performed.Results Serum levels of ALT,AST,FPG,FINS and HOMA-IR were significantly higher in NASH group than in normal control group(P0.01).Compared with NASH group,serum levels of ALT,FPG, FINS and HOMA-IR decreased significantly(P0.01),and AST level also decreased,but with no significance(P0.05).Telmisartan improved significantly hepatic inflammation and fibrosis(P0.01),decreased HOMA-IR significantly(P0.01),reduced expresseions ofα-SMA and TIMP-1,and increased expressions of MMP-13 in hepatic tissue(P0.01).Conclusion Telmisartan can improve insulin resistance and prevent hepatic fibrosis in NASH rats.","PeriodicalId":10086,"journal":{"name":"中华老年多器官疾病杂志","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华老年多器官疾病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3724/sp.j.1264.2011.00018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective To study the effects of telmisartan on matrix metalloproteinase-13(MMP-13) and tissue inhibitor of metallo- proteinase-1(TIMP-1) expressions and insulin resistance in rat model of nonalcoholic steatohepatitis(NASH).Methods Thirty male SD rats were randomized into normal control group,NASH model group and telmisartan intervention group.The rats were given standard food in normal control group,while high fat diet for 16 weeks in the other two groups to induce NASH.In telmisartan intervention group, telmisartan[5 mg/(kg·d)]was adminstrated intragastrically for 4 weeks since the 12th week.All animals were sacrificed at 16 weeks. Serum levels of alanine aminotransferase(ALT),aspartate transaminase(AST),fasting blood glucose(FBG) and fasting insulin(FINS) were detected.Insulin sensitivity was evaluated by homeostasis model assessment of insulin resistance(HOMA-IR).Western blot and RT-PCR were used to measure TIMP-1 and MMP-13 expressions in hepatic tissue.Histological observation and immunohistochemical staining ofα-smooth muscle actin(α-SMA) were also performed.Results Serum levels of ALT,AST,FPG,FINS and HOMA-IR were significantly higher in NASH group than in normal control group(P0.01).Compared with NASH group,serum levels of ALT,FPG, FINS and HOMA-IR decreased significantly(P0.01),and AST level also decreased,but with no significance(P0.05).Telmisartan improved significantly hepatic inflammation and fibrosis(P0.01),decreased HOMA-IR significantly(P0.01),reduced expresseions ofα-SMA and TIMP-1,and increased expressions of MMP-13 in hepatic tissue(P0.01).Conclusion Telmisartan can improve insulin resistance and prevent hepatic fibrosis in NASH rats.
期刊介绍:
Chinese Journal of Multiple Organ Diseases in the Elderly (monthly) is a medical academic journal under the supervision of PLA General Hospital, sponsored by PLA General Hospital Medical Innovation Research Department, National Clinical Medical Research Center for Geriatric Diseases (PLA General Hospital), and Department of Cardiovascular Medicine of the Sixth Medical Center of PLA General Hospital, and publicly issued at home and abroad. This journal was founded in June 2002 and is a Chinese Science and Technology Paper Statistical Source Journal (China Science and Technology Core Journal), and is included in major domestic retrieval systems and well-known domestic and foreign retrieval systems such as the American Chemical Abstracts.
As the only academic journal in China that reflects multi-organ diseases in the elderly, Chinese Journal of Multiple Organ Diseases in the Elderly mainly exchanges the diagnosis and treatment experience and lessons of cardiovascular diseases in the elderly, especially cardiovascular diseases in the elderly combined with other diseases, diseases of more than two organs in the elderly, and other multiple diseases in the elderly, explores their pathogenesis and effective diagnosis and treatment measures, and focuses on reporting the latest clinical, basic and preventive achievements and experiences in the research of the above diseases in my country with innovative significance; the main readers are medical, scientific research and teaching personnel engaged in geriatric cardiology and (or) geriatric medicine and related diseases.
The main columns include expert comments, special forums, clinical research, basic research, clinical pharmacy, case reports, new technologies and methods, clinical pathology discussions, reviews, academic trends, expert popular science lectures, etc.